These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 33218740)

  • 1. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
    Ramaswami U; Beck M; Hughes D; Kampmann C; Botha J; Pintos-Morell G; West ML; Niu DM; Nicholls K; Giugliani R;
    Drug Des Devel Ther; 2019; 13():3705-3715. PubMed ID: 31749608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
    Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
    Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey.
    Nowak A; Botha J; Anagnostopoulou C; Hughes DA
    Mol Genet Metab; 2024; 143(1-2):108561. PubMed ID: 39159540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis.
    Hughes D; Linhart A; Gurevich A; Kalampoki V; Jazukeviciene D; Feriozzi S;
    Drug Des Devel Ther; 2021; 15():3561-3572. PubMed ID: 34429585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.
    Ferrari G; Kisinovsky I; Reisin R; Rozenfeld P; Neumann P; Finn V; Marchesoni C; Quieto P;
    Medicina (B Aires); 2024; 84(3):516-525. PubMed ID: 38907966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
    Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
    J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
    Beck M; Hughes D; Kampmann C; Larroque S; Mehta A; Pintos-Morell G; Ramaswami U; West M; Wijatyk A; Giugliani R;
    Mol Genet Metab Rep; 2015 Jun; 3():21-7. PubMed ID: 26937390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
    Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
    Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
    J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
    Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
    Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.